Mangoceuticals converts $150K note into 100K shares; appoints Antonios Isaac as President & Director

MANGOCEUTICALS, INC.

Debt conversion with Mill End Capital: $150K promissory note converted to 100K restricted common shares at $1.50/share.
Antonios Isaac appointed as Director and President; enters 12-month consulting agreement at $10K/month.
Final 250 shares of Series B Preferred Stock sold for $250K, completing Fourth Closing under 2024 SPA.
Conversion of note triggers anti-dilution repricing: all outstanding warrants and Series B conversion price adjusted to $1.50/share.

item 1.01 item 5.02 item 3.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Antonios Isaac

President

MGRX · MANGOCEUTICALS, INC.

Effective: 2025-01-15
Filed: January 21, 2025, 6:59 PM ET

appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.

Appointed

Antonios Isaac

Director

MGRX · MANGOCEUTICALS, INC.

Effective: 2025-01-15
Filed: January 21, 2025, 6:59 PM ET

appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Antonios Isaac was appointed as President at MANGOCEUTICALS, INC..

Action: appointed
Role: President

Exact text from the filing

appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Antonios Isaac was appointed as Director at MANGOCEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.

View on SEC.gov

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-003054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.